Publications by authors named "H K Yap"
Article Synopsis
- Soft robotics is being explored for rehabilitation, offering potential benefits for individuals recovering upper limb motor function after injuries, with an emphasis on increased safety and comfort compared to traditional rigid robotics.
- The article reviews clinical evidence from 37 studies on 13 different soft upper limb devices used in both clinical and home environments, assessing their effectiveness and user experience.
- It aims to guide future developments in soft robotic rehabilitation by providing recommendations for design and application, highlighting the importance of understanding user needs and clinical outcomes.
Background: In endemic COVID-19, immunocompromised children are vulnerable until vaccinated but the optimal primary vaccination regime and need for booster doses remains uncertain.
Methods: We recruited 19 immunocompromised children (post-solid organ transplantation, have autoimmune disease or were on current or recent chemotherapy for acute lymphoblastic leukemia), and followed them from the start of primary vaccination with BNT162b2 mRNA SARS-CoV-2 until 1-year post-vaccination. We investigated the quality of vaccine immunogenicity, and longevity of hybrid immunity, in comparison to healthy children.
Heart failure (HF) prevalence is rising due to population aging and increasing risk factor incidence, thereby posing a significant global public health challenge. Disease management programs (DMPs) play a crucial role in managing HF and optimizing postevent health outcomes. Through a systematic review and meta-analysis, this study aimed to evaluate the effectiveness of DMPs following an HF event.
View Article and Find Full Text PDFArticle Synopsis
- The study investigated the effectiveness and safety of rituximab for treating childhood steroid-resistant nephrotic syndrome (SRNS) across 28 pediatric nephrology centers globally.
- Researchers found that children with a longer history of calcineurin inhibitors (CNIs) treatment before rituximab had lower remission rates compared to those with shorter treatment periods.
- Overall, rituximab showed enhanced remission rates in a portion of SRNS patients, was mostly safe, and achieving complete remission was linked to better kidney survival outcomes.
Infection-related complications remain the most significant cause for morbidity and technique failure in infants, children and adolescents who receive maintenance peritoneal dialysis (PD). The 2024 update of the Clinical Practice Guideline for the Prevention and Management of Peritoneal Dialysis Associated Infection in Children builds upon previous such guidelines published in 2000 and 2012 and provides comprehensive treatment guidance as recommended by an international group of pediatric PD experts based upon a review of published literature and pediatric PD registry data. The workgroup prioritized updating key clinical issues contained in the 2012 guidelines, in addition to addressing additional questions developed using the PICO format.
View Article and Find Full Text PDF